Your patients are on these medications. Or they are asking about them. Or they have already started and are sitting in your office wondering why they feel worse in some ways even as the scale moves in the right direction.
Semaglutide and tirzepatide have fundamentally changed the weight loss landscape, and as functional medicine practitioners, our role is not to take a political stance on whether patients should or should not use them. Our role is to understand what these drugs do, what they miss, and where our skill set fills the gaps that prescribing providers are not addressing. Because there are significant gaps, and for practitioners who work with hormones, thyroid function, gut health, and nutrient status, those gaps land squarely in your clinical territory.
Why Perimenopause Changes the Metabolic Equation
Before we talk about the risks, it is worth understanding why these medications are so appealing to the midlife patient population, and why the clinical conversation is more nuanced than “weight loss drug, yes or no.”
The metabolic shift that occurs during perimenopause is not simply about aging. It is hormonally driven. As estrogen declines, insulin sensitivity decreases. Cells become less responsive to insulin, and the body compensates by producing more of it, which drives fat storage, particularly visceral fat around the midsection. Resting metabolic rate drops as lean mass declines. Fat distribution shifts from peripheral to central. The mechanisms that used to respond predictably to caloric restriction and exercise become less reliable. This is not a willpower problem. It is a physiological reorganization.
For many women, this metabolic disruption begins years before their final menstrual period. Early perimenopause brings progesterone decline and erratic estrogen levels. By mid-perimenopause, insulin resistance is developing or worsening, cycles are becoming irregular, and visceral fat accumulation is underway. By late perimenopause and early postmenopause, these metabolic changes are entrenched.
GLP-1 receptor agonists address several of these disruptions simultaneously. They improve insulin sensitivity, reduce appetite centrally, and facilitate weight loss in a population where traditional approaches have often plateaued. RAND survey data shows that women aged 50-64 have the highest GLP-1 use overall, with 20% reporting current or past use. Perimenopausal women are not incidental users of these medications. They are the primary demographic.
The Case for Low-Dose and Microdosing Approaches
Data from the SUSTAIN clinical trial program demonstrates that even the lowest approved dose of semaglutide (0.5 mg weekly, well below the 2.4 mg weight loss dose) produces clinically significant improvements in HbA1c and insulin sensitivity in type 2 diabetes populations. There is growing clinical interest in whether these lower doses, sometimes referred to as microdosing, may offer metabolic benefit for perimenopausal women dealing with early insulin resistance and metabolic disruption without the GI side effects that drive many women to discontinue treatment at higher doses. The biological rationale is strong: GLP-1 receptor signaling is dose-responsive, and even partial activation appears to influence insulin sensitivity and inflammatory pathways. However, dedicated clinical trials in this specific population are still needed. What we can say is that the mechanistic overlap between what these medications do and what perimenopause disrupts, insulin sensitivity, appetite regulation, visceral fat accumulation, is difficult to ignore.
This is relevant for functional practitioners because the clinical goal in many of these patients is not dramatic weight loss. It is metabolic stabilization: restoring insulin sensitivity, interrupting the visceral fat accumulation cycle, and creating conditions where hormone optimization and lifestyle interventions can perform. Low-dose GLP-1 therapy, used as a metabolic tool rather than a weight loss drug, may have a meaningful role in this population when paired with the right clinical framework.
There is also emerging data suggesting that GLP-1 tolerability and efficacy vary with the hormonal cycle, and that higher circulating estrogen levels are associated with increased nausea and vomiting on these medications. Women experience GI side effects at up to 2.5 times the rate of men. Personalized dosing, including cycle-aware dosing in premenopausal patients, may become an important clinical consideration.
The Synergy Between HRT and GLP-1 Therapy
Perhaps the most compelling recent data for hormone-focused practitioners comes from a 2026 study published in The Lancet Obstetrics, Gynaecology, and Women’s Health. Researchers at Mayo Clinic found that postmenopausal women who used tirzepatide alongside hormone therapy lost approximately 35% more weight than women taking tirzepatide alone. The combined group also showed greater improvements in blood pressure, blood sugar, and cardiometabolic parameters.
This is not a surprise if you understand the physiology. Estrogen supports insulin sensitivity, preserves lean mass, modulates fat distribution, and reduces inflammation. When you restore estrogen in a postmenopausal woman and simultaneously address metabolic dysfunction with a GLP-1 agonist, you are working two sides of the same equation. The hormones create a more responsive metabolic environment. The GLP-1 agonist leverages that environment to produce better outcomes.
For functional practitioners, this reinforces what we already know: hormones do not operate in isolation, and the best clinical outcomes come from understanding how interventions interact. A patient on GLP-1 therapy without hormone optimization may be leaving significant metabolic benefit on the table. A patient on HRT without metabolic support may plateau. The combination, when clinically appropriate, appears to be genuinely synergistic.
The Lean Mass Problem
This is the conversation that is not happening in most prescribing offices. When patients lose weight on GLP-1 receptor agonists, they are not losing only fat. Research consistently shows that approximately 25-40% of total weight lost on these medications comes from lean mass. The most potent agents, tirzepatide at 15 mg weekly and semaglutide at 2.4 mg weekly, are the most effective for total weight reduction but among the least effective at preserving lean mass.
For midlife women, this is a clinical priority. Women in perimenopause and menopause are already losing lean mass due to declining estrogen and testosterone. When you layer GLP-1-mediated muscle loss on top of hormonally-driven decline, you create a compounding problem: reduced metabolic rate, decreased bone density stimulus, and an accelerated trajectory toward frailty. This is the patient who loses 40 pounds, fits into smaller clothes, and yet feels weaker and more fatigued than before.
Body composition monitoring via DEXA whole body scans should be standard of care for any patient on GLP-1 therapy. Protein intake (minimum 1.2-1.6 g/kg ideal body weight daily) and resistance training are non-negotiable companions to these medications. Research shows that patients who prioritize both can dramatically reduce lean mass loss, with some case reports showing actual lean mass gains despite significant total weight reduction.
And here is where it comes full circle: adequate estrogen and testosterone status may be protective against lean mass loss during GLP-1 therapy. This creates a clinical argument for hormone optimization alongside GLP-1 use that most prescribers are not making, and it is consistent with the Lancet data showing superior outcomes when HRT and GLP-1 therapy are combined.
Thyroid Considerations
The thyroid conversation around GLP-1 agonists typically begins and ends with the FDA black box warning regarding C-cell tumors in rodent studies. Large-scale human trials have not confirmed this finding. But the more clinically relevant concern has nothing to do with C-cell tumors. It has to do with what rapid caloric restriction does to thyroid physiology.
When caloric intake drops substantially, the body downregulates active thyroid hormone production. T4-to-T3 conversion slows. Reverse T3 rises. The patient becomes functionally hypothyroid even if TSH remains within conventional range. For patients already on the edge of optimal thyroid function, this shift can be significant. Symptoms attributed to “adjustment” on the new medication may actually be newly emergent thyroid hypofunction.
Additionally, GLP-1 agonists delay gastric emptying, which changes the absorption kinetics of oral medications including levothyroxine. Case reports have documented TSH shifts in patients on previously stable thyroid doses after initiating semaglutide. For any patient on or starting GLP-1 therapy, a full thyroid panel (TSH, free T4, free T3, reverse T3, antibodies) should be part of baseline and ongoing monitoring, with increased frequency during the first 6-12 months.
Nutrient Depletion
Patients on GLP-1 agonists eat significantly less food. That is how the medication works. But less food often means less nutrient intake, and when you combine reduced intake with altered gastric motility and absorption patterns, you create conditions for meaningful depletion. A large observational study of over 461,000 adults found that 22% were newly diagnosed with a nutritional deficiency within 12 months of starting therapy.
Key nutrients at risk include B12 (impaired GI absorption compounds reduced intake), iron (prospective data show reduced intestinal absorption with semaglutide specifically), fat-soluble vitamins A, D, E, and K (reduced dietary fat impairs absorption), magnesium and zinc (both commonly insufficient at baseline in metabolic patients), and thiamine (rapid weight loss depletes stores quickly, with case reports of neurological emergencies in severe deficiency). No consensus guidelines currently exist for micronutrient monitoring in patients on GLP-1 receptor agonists. That gap falls to practitioners who are actually looking.
Hormone Interactions
This is where the functional medicine framework adds depth that conventional management is missing entirely.
Adipose tissue produces estrogen via aromatase activity. Rapid fat mass loss means rapid loss of an endogenous estrogen source. For women on HRT, the protocol that worked at 200 pounds may not be the right protocol at 160 pounds. Weight loss also increases SHBG, which binds free testosterone and estradiol, reducing bioavailability. This is the patient who reports losing 30 pounds but feeling worse: lower energy, vanished libido, worsened brain fog. By conventional metrics, things are improving. By free hormone levels, they are not.
Significant caloric restriction is also a physiological stressor that can increase cortisol output and compromise progesterone production. For perimenopausal women already managing progesterone insufficiency, this adds another layer of disruption that may be mistaken for disease progression rather than metabolic stress.
And the rebound question matters: research shows 60-163% of weight lost on GLP-1 agonists (conventional dosing) is regained after discontinuation, bringing its own hormonal recalibration that most prescribers are not preparing patients for.
Your Role
You do not need to prescribe these medications to play a critical clinical role. Baseline and ongoing monitoring of thyroid, hormones (including free fractions and SHBG), nutrients, and body composition positions you as an essential part of the care team. Frame your role as complementary, not competitive. Most prescribers welcome a practitioner managing the systems that fall outside their 15-minute follow-up.
GLP-1 receptor agonists are not going away. The question is whether your patients on these medications are being comprehensively managed. Right now, for most of them, the answer is no. The practitioner who understands these intersections does not oppose pharmaceutical intervention. They complete it. And the emerging data on HRT and GLP-1 synergy is a powerful reminder that the work we do in hormone optimization is not separate from metabolic medicine. It is central to it.
